Favorable Impact of Growth Hormone Treatment on Cholesterol Levels in Turner Syndrome

Background: Patients with Turner syndrome (TS) are prone to having metabolic abnormalities, such as obesity, dyslipidemia, hypertension, hyperinsulinemia and type 2 diabetes mellitus, resulting in increased risks of developing atherosclerotic diseases. Objective: To determine the effect of growth hormone (GH) therapy on serum cholesterol levels in prepubertal girls with TS enrolled in the Turner syndrome Research Collaboration (TRC) in Japan. Patients and methods: Eighty-one girls with TS were enrolled in the TRC, and their total cholesterol (TC) levels before GH therapy were compared with reported levels of healthy school-aged Japanese girls. TC levels after 1, 2 and 3 yr of GH treatment were available for 28 of the 81 patients with TS. GH was administered by daily subcutaneous injections, 6 or 7 times/wk, with a weekly dose of 0.35 mg/kg body weight. Results: Baseline TC levels revealed an age-related increase in TS that was in contrast to healthy girls showing unchanged levels. During GH therapy, TC decreased significantly after 1 yr of GH treatment and remained low thereafter. Conclusions: Girls with untreated TS showed an age-related increase in TC that was a striking contrast to healthy girls, who showed unchanged levels. GH therapy in girls with TS brought about a favorable change in TC that indicates the beneficial impact of GH on atherogenic risk.

[1]  A. Swerdlow,et al.  Mortality in women with turner syndrome in Great Britain: a national cohort study. , 2008, The Journal of clinical endocrinology and metabolism.

[2]  Svend Juul,et al.  Prevalence, incidence, diagnostic delay, and mortality in Turner syndrome. , 2006, The Journal of clinical endocrinology and metabolism.

[3]  C. Bondy,et al.  Monosomy for the X-chromosome is associated with an atherogenic lipid profile. , 2006, The Journal of clinical endocrinology and metabolism.

[4]  Jimmy D Bell,et al.  Excess visceral and hepatic adipose tissue in Turner syndrome determined by magnetic resonance imaging: estrogen deficiency associated with hepatic adipose content. , 2005, The Journal of clinical endocrinology and metabolism.

[5]  D. Stephure.  Impact of growth hormone supplementation on adult height in turner syndrome: results of the Canadian randomized controlled trial. , 2005, The Journal of clinical endocrinology and metabolism.

[6]  T. Stijnen,et al.  Effect of discontinuation of long-term growth hormone treatment on carbohydrate metabolism and risk factors for cardiovascular disease in girls with Turner syndrome. , 2002, The Journal of clinical endocrinology and metabolism.

[7]  L. Mosekilde,et al.  Short-term growth hormone treatment in girls with Turner syndrome decreases fat mass and insulin sensitivity: a randomized, double-blind, placebo-controlled, crossover study. , 2002, Pediatrics.

[8]  A. Pasquino,et al.  Recommendations for the diagnosis and management of Turner syndrome. , 2001, The Journal of clinical endocrinology and metabolism.

[9]  S. Zucchini,et al.  Reduced spontaneous growth hormone secretion in patients with Turner's syndrome , 1999, Acta paediatrica.

[10]  G. Conway,et al.  The impact of obesity on cardiovascular risk factors in Turner's syndrome , 1998, Clinical endocrinology.

[11]  C. Gicquel,et al.  Assessment of Turner's syndrome by molecular analysis of the X chromosome in growth-retarded girls. , 1998, The Journal of clinical endocrinology and metabolism.

[12]  C. Gravholt,et al.  Morbidity in Turner syndrome. , 1998, Journal of clinical epidemiology.

[13]  K. Tachibana,et al.  Clinical trials of GH treatment in patients with Turner's syndrome in Japan--a consideration of final height. The Committee for the Treatment of Turner's Syndrome. , 1997, European journal of endocrinology.

[14]  V. Sybert,et al.  Turner's syndrome. , 1996, The New England journal of medicine.

[15]  W. Fraser,et al.  Undiagnosed morbidity in adult women with Turner's syndrome , 1996, Clinical endocrinology.

[16]  J. Ross,et al.  Lipid abnormalities in Turner syndrome. , 1995, The Journal of pediatrics.

[17]  M. Hassan,et al.  Magnetic resonance imaging evaluation of adipose tissue and muscle tissue mass in children with growth hormone (GH) deficiency, Turner's syndrome, and intrauterine growth retardation during the first year of treatment with GH. , 1994, The Journal of clinical endocrinology and metabolism.

[18]  P. Hindmarsh,et al.  Growth hormone secretion in patients with Turner's syndrome as determined by time series analysis. , 1992, Acta endocrinologica.

[19]  H. Kohno,et al.  Low urinary growth hormone values in patients with Turner's syndrome. , 1992, The Journal of clinical endocrinology and metabolism.

[20]  M. Ranke,et al.  Growth hormone, somatomedin levels and growth regulation in Turner's syndrome. , 1987, Acta endocrinologica.

[21]  R. de Mey,et al.  Mortality ratios, life expectancy, and causes of death in patients with Turner's syndrome. , 1986, Journal of epidemiology and community health.

[22]  C. Bondy,et al.  Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. , 2007, The Journal of clinical endocrinology and metabolism.

[23]  T. Okada,et al.  New criteria of normal serum lipid levels in Japanese children: the nationwide study. , 2002, Pediatrics international : official journal of the Japan Pediatric Society.

[24]  G. Haeusler,et al.  Short- and long-term (final height) growth responses to growth hormone (GH) therapy in patients with Turner syndrome: correlation of growth response to stimulated GH levels, spontaneous GH secretion, and karyotype. , 1997, Hormone research.

[25]  T. J. Gargan.  Turner's syndrome. , 1997, The New England journal of medicine.